Treatment of early-stage lung adenocarcinoma with Lifei Xiaoji Wan
Study on the Therapeutic Effect of Lifei Xiaoji Wan on Lung Adenocarcinoma in the Early Stage of Ground Glass Nodule (Ia Stage) and Its Effect on Tumor Microenvironment
This study is testing if a traditional Chinese medicine called Lifei Xiaoji Wan can help people with early-stage lung adenocarcinoma by looking at how it affects their tumors compared to standard Western treatments.
Quick facts
| Phase | Not applicable |
|---|---|
| Study type | Interventional |
| Enrollment | 40 (estimated) |
| Ages | 18 Years to 75 Years |
| Sex | All |
| Sponsor | Henan University of Traditional Chinese Medicine Academic / other |
| Locations | 1 site (Zhengzhou) |
| Trial ID | NCT06387134 on ClinicalTrials.gov |
What this trial studies
This study evaluates the effectiveness of Lifei Xiaoji Wan, a traditional Chinese medicine, in treating early-stage lung adenocarcinoma, particularly focusing on its impact on the tumor microenvironment. It employs a single-center randomized controlled design with a treatment group receiving Lifei Xiaoji Wan and a control group receiving conventional Western medicine. The study aims to provide high-level clinical evidence and insights into the mechanisms by which this treatment may influence tumor behavior and patient outcomes.
Who should consider this trial
Good fit: Ideal candidates include adults aged 18-75 with early-stage lung adenocarcinoma confirmed by pathology and presenting with specific ground glass nodules.
Not a fit: Patients who have undergone surgery for lung cancer or those with serious organ dysfunction or mental illness may not benefit from this study.
Why it matters
Potential benefit: If successful, this treatment could offer a novel therapeutic option for patients with early-stage lung adenocarcinoma, potentially improving their prognosis and quality of life.
How similar studies have performed: While traditional Chinese medicine has been explored in various contexts, this specific approach using Lifei Xiaoji Wan in early-stage lung adenocarcinoma is relatively novel and lacks extensive prior clinical validation.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * It met the diagnostic criteria of non-small cell lung cancer and was confirmed by pathology, cytology and other relevant examinations. * Preoperative thin-slice CT showed pure ground glass pulmonary nodules with a size of 10mm-30mm. Intraoperative and postoperative pathology indicated adenocarcinoma, and the tumor stage (TNM) was stage Ia. * Age: 18-75 years old * Expected survival \>5 years * Informed consent and sign informed consent Exclusion Criteria: * Patients who have undergone surgery * Patients with serious dysfunction of heart, liver, lung, kidney and other important organs * Patients with mental illness who were unable to complete the study
Where this trial is running
Zhengzhou
- Mingli Zhao — Zhengzhou, China (Recruiting)
Study contacts
- Study coordinator: Mingli Zhao, MD
- Email: 13937159120@163.com
- Phone: 0371-66246152
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.